order
add
potenti
cytoprotect
function
jiandong
huang
oligooxaadamantan
recent
conjug
depart
biochemistri
vitamin
pyridox
creat
new
class
depart
microbiolog
mantanesth
bananin
figur
depart
chemistri
size
six
bananin
derivativesbananin
ban
iodobaopen
laboratori
chemic
biolog
nanin
ibn
adeninobananin
adn
vanillinbananin
vbn
univers
hong
kong
pokfulam
eubananin
eub
ansabananin
abn
synthehong
kong
china
si
bananin
describ
synthesi
ibn
center
emerg
infecti
diseas
adn
report
elsewher
ajk
submit
faculti
medicin
final
three
describ
report
chines
univers
hong
kong
sever
acut
respiratori
syndrom
sar
caus
hong
kong
china
infect
sar
coronaviru
scv
germani
scv
rapidli
sequenc
follow
identif
lead
recognit
number
possibl
drug
target
although
treatment
ribavirin
corticosteroid
shown
slight
posisummari
tive
effect
sideeffect
lack
activ
ribavirin
cell
cultur
highlight
need
bananin
class
antivir
compound
effect
treatment
recent
antiscv
drug
develuniqu
structur
signatur
incorpor
trioxaop
target
viral
main
proteas
also
adamantan
moieti
coval
bound
pyridox
call
proteas
follow
initi
crystal
deriv
six
member
class
compound
structur
structur
togeth
inhibitor
bananin
iodobananin
vanillinbananin
ansabananin
solv
class
boronicacidbas
proteeubananin
adeninobananin
synthes
ase
inhibitor
also
identifi
largetest
inhibitor
sar
coronaviru
scv
scale
screen
identifi
scv
inhibitor
effect
helicas
bananin
iodobananin
vanillinbananin
proteas
collabor
eubananin
effect
inhibitor
atpas
acalso
recent
identifi
inhibitor
scv
helicas
tiviti
scv
helicas
ic
valu
rang
proteas
spikemedi
viral
entri
similar
trend
though
slightli
higher
ical
genet
approach
paper
focu
inhibitor
concentr
observ
inhibit
specif
scv
ntpasehelicas
drug
targetof
helicas
activ
use
fretbas
fluores
viral
helicas
mark
success
anim
cent
assay
cell
cultur
system
scv
bananin
model
herp
simplex
viru
exhibit
ec
less
cc
progress
target
hepatati
c
viru
heliov
kinet
inhibit
consist
case
previous
clone
purifi
perbananin
inhibit
intracellular
process
proform
initi
biochem
character
cess
involv
scv
replic
scv
helicas
result
show
helicas
exhibit
strict
polar
consist
conintroduct
temporari
report
anoth
group
also
shown
recent
scv
helicas
possess
adamantan
formal
design
tricyclo
rna
triphosphatas
activ
may
involv
decan
structur
unusu
compound
cap
viral
rna
four
cyclohexan
ring
fuse
parth
scv
helicas
consist
three
major
domainsticularli
strainfre
chair
conform
oligooxaa
put
ntermin
metal
bind
domain
mbd
adamantan
contain
oxygen
place
methylen
hing
domain
ntpasehelicas
domain
linkag
within
structur
play
varieti
role
clear
previou
work
anoth
member
niin
natur
infam
neurotoxin
puffer
doviral
order
equin
arteriviru
eav
metal
fish
tora
fugu
tetrodotoxin
ttx
figur
plant
bind
domain
essenti
viral
viabil
natur
product
steroid
daigremontianin
also
like
case
close
relat
scv
adamantan
deriv
extrem
toxic
paper
investig
effect
bananin
mani
synthet
deriv
amantadin
seri
compound
atpas
helicas
use
clinic
figur
amantadin
use
activ
scv
helicas
also
test
bananin
antivir
agent
muscl
relax
treatagainst
scv
cell
cultur
find
bananin
three
deriv
potent
inhibitor
atpas
helicas
activ
scv
helicas
correspond
andreaskesel
tonlined
ajk
jdhuang
hkucc
bananin
inhibit
scv
replic
concentr
hkuhk
jdh
author
contribut
equal
work
significantli
toxic
cell
hr
mayer
em
paulshock
watt
jc
wood
tr
hermann
ec
hoffmann
ce
antivir
activ
infect
cytopath
effect
cpe
observ
phasecontrast
microscopi
uninfect
cell
appear
smooth
mantanamin
amantadin
scienc
schwab
rs
england
ac
jr
poskanz
dc
young
infect
cell
show
promin
ridgelik
structur
along
membran
viral
reproduct
infect
cell
quantifi
rr
amantadin
treatment
parkinson
diseas
jama
viru
titrat
describ
wintermey
sm
nahata
mc
rimantadin
clinic
perspect
ann
pharmacoth
inhibit
scv
reproduct
rosenth
ks
sokol
ms
ingram
rl
subramanian
r
cell
cultur
infect
scv
one
hour
fort
rc
tromantadin
inhibitor
earli
late
treat
variou
concentr
drug
follow
event
herp
simplex
viru
replic
antimicrob
agent
incub
hr
viabl
scv
product
measur
chemoth
back
titrat
cultur
media
supernat
use
tcid
kornhub
j
weller
schoppmey
k
rieder
p
tissu
cultur
infecti
dose
protocol
briefli
su
amantadin
memantin
nmda
receptor
antagpernat
serial
dilut
fresh
cell
cultur
media
onist
neuroprotect
properti
j
neural
transm
mem
inocul
cell
plate
viru
suppl
titr
determin
observ
cytopath
effect
cpe
kesel
aj
sonnenbichl
polborn
k
gurtler
l
klinkert
cell
day
cultur
modolel
nussler
ak
oberthur
w
new
antioxid
vitamin
analogu
modul
pathophysiqrtpcr
olog
cell
prolifer
damag
bioorg
med
chem
cell
wash
twice
pb
total
rna
extract
use
rneasi
mini
kit
qiagen
germani
accord
kesel
aj
system
protein
target
sequenc
manufactur
instruct
reversetranscript
perform
antirnavir
chemotherapi
vitamin
zincus
random
hexam
thermoscript
rt
system
invitrochel
trioxaadamantanetriol
bioorg
med
chem
gene
ca
intracellular
viral
rna
quantifi
use
quantit
rtpcr
qrtpcr
use
forward
primer
gct
tag
gcc
ctt
tga
gag
aga
revers
primer
nm
fluoresc
probe
cct
gat
ggc
aaa
cct
tgc
coronaviru
possibl
caus
sever
acut
respiratori
phosphat
probe
cac
ctg
ctc
tta
att
gtt
att
syndrom
lancet
ggc
final
concentr
nm
realtim
quantif
ksiazek
tg
erdman
goldsmith
cs
zaki
sr
peret
carri
use
lc
faststart
dna
master
hyb
probe
emeri
tong
urbani
c
comer
ja
lim
w
et
al
lightcycl
roch
diagnost
usa
pcr
condit
employ
novel
coronaviru
associ
sever
acut
respiwer
min
cycl
ratori
syndrom
n
engl
j
med
increas
pcr
product
drosten
c
gunther
preiser
w
van
der
werf
brodt
monitor
amplif
cycl
measur
hr
becker
rabenau
h
pan
kolesnikova
l
increas
fluoresc
caus
bind
sybr
green
fouchier
ra
et
al
identif
novel
corodoublestrand
dna
cross
point
valu
determin
naviru
patient
sever
acut
respiratori
syndrom
n
sampl
specif
amplicon
measur
engl
j
med
melt
curv
analysi
visual
agaros
gel
rota
pa
oberst
ms
monro
ss
nix
wa
campagnoli
si
tenfold
serial
dilut
plasmid
rang
pgml
r
icenogl
jp
penaranda
bankamp
b
maher
k
pgml
use
standard
gene
chen
mh
et
al
character
novel
corous
endogen
control
normal
intersampl
varianaviru
associ
sever
acut
respiratori
syndrom
tion
amount
total
rna
cell
cultur
studi
suggest
bananin
inhibour
knowledg
array
complet
new
adamantan
deriv
may
easili
diversifi
reit
intracellular
activ
mechanist
involv
key
viral
process
oppos
viral
entri
step
act
variou
aromat
aldehyd
phloroglucinol
result
consist
class
drug
target
scv
helicas
within
cell
previous
develop
colorimetr
assay
measur
ntpase
activ
scv
helicas
well
plate
high
throughput
format
discontinu
colorimetr
assay
use
malachit
synthesi
bananin
deriv
bananin
synthes
reaction
green
ammonium
molybd
releas
phosphat
quantifi
min
reaction
period
observ
phloroglucinol
like
triketo
tautomer
form
aromat
aldehyd
catalyz
hydrochlor
wavelength
nm
oligodt
includ
assay
satur
concentr
nm
mimic
acid
sodium
hydroxid
aqueou
solut
gener
acid
catalysi
use
due
degrad
nucleic
acidstimul
ntpase
activ
scv
helicas
potenti
inhibitor
atpas
reaction
pyridox
highli
basic
condit
alkalin
catalysi
use
reaction
aromat
aldehyd
would
expect
reduc
amount
phosphat
releas
reaction
reflect
decreas
vanillin
bananin
synthesi
driven
creation
highli
symmetr
trioxaadamantanetriol
measur
absorb
nm
first
check
whether
bananin
compound
tat
cage
system
prototyp
compound
tat
seri
vitamin
b
deriv
bananin
ban
abl
inhibit
dt
stimul
atpas
activ
scv
helicas
control
carri
hydroxymethyl
iodin
sure
bananin
compound
affect
phosphat
measur
assay
reaction
subsequ
oxid
iodobananin
iodobananin
carboxyl
acid
ibn
iodin
ibn
carri
presenc
variou
concentr
six
bananin
deriv
result
replac
variou
substitu
exemplifi
synthesi
adeninobananin
adeninobananin
plot
fit
simpl
model
figur
also
check
reaction
condit
carboxyl
acid
hydrochlorid
adn
use
activ
adenin
nucleobas
deriv
interestingli
ban
make
measur
within
linear
region
figur
suscept
michael
addit
natur
product
eugenol
isol
essenti
oil
clove
result
show
parent
compound
bananin
inhibit
atpas
activ
scv
helicas
syzygium
aromaticum
naohcatalyz
addit
lead
eugenolbananin
eubananin
eub
atpas
ic
valu
ic
valu
shown
figur
iodobananin
vanillinbananin
exhibb
transform
cyclic
hemiket
condens
ansacompound
ansabananin
abn
inspir
ite
strongest
inhibit
atpas
ic
valu
respect
inhibit
vanillinbaansamycin
rifamycin
geldanamycin
aromat
aldehyd
seri
vanillin
react
nanin
indic
presenc
sixmemb
nitrogen
heterocycl
absolut
essenti
inwith
phloroglucinol
yield
vanillinbananin
vbn
activ
eubananin
show
similar
inhibitori
activ
bananin
atpas
ic
expect
numer
natur
occur
aldehyd
introduc
form
corinterestingli
ansabananin
weak
inhibitor
atpas
ic
adeninobananin
show
respond
tat
phloroglucinol
aqueou
naoh
bananin
group
compound
repres
inhibitori
activ
result
suggest
doubl
reciproc
lineweav
burk
plot
data
figur
case
v
max
significantli
decreas
presenc
inhibitor
k
chang
littl
indic
bananin
act
noncompetit
inhibitor
atpas
activ
scv
helicas
respect
atp
nucleic
acid
suggest
bananin
inhibit
bind
site
distinct
atp
nucleic
acid
bind
site
build
foundat
next
test
antihelicas
activ
compound
use
newli
develop
fluorimetr
assay
base
strong
fluoresc
reson
energi
transfer
fret
fluorophor
quencher
black
hole
quencher
similar
approach
outlin
recent
assay
hepat
c
viru
hcv
helicas
helicas
howev
recent
shown
scv
helicas
hold
strict
direction
design
system
oligo
dt
overhang
principl
behind
new
assay
outlin
figur
fluorophor
end
one
oligom
duplex
close
proxim
quencher
end
oligom
two
oligom
close
proxim
ie
two
oligom
anneal
fluoresc
strongli
quench
fret
effect
duplex
unwound
scv
helicas
fluoresc
longer
quench
dramat
increas
fluoresc
may
observ
ensur
primer
reanneal
second
captur
primer
includ
reaction
ident
primer
contain
quench
group
therefor
anneal
process
littl
effect
fluoresc
optim
reaction
condit
ensur
measur
carri
linear
region
figur
one
minut
timepoint
linear
region
probe
larger
atpas
ic
valu
observ
inhibitor
follow
gener
trend
observ
atpas
data
bananin
iodobabulki
side
group
sixmemb
ring
nanin
vanillinbananin
eubananin
effect
inclass
compound
reduc
inhibitori
activ
hibitor
helicas
activ
ansabanin
adenagainst
scv
helicas
inobananin
bare
inhibit
reaction
also
check
whether
bananin
would
inhibit
also
perform
final
control
check
whether
unstimul
basal
atpas
activ
absenc
bananin
act
gener
helicas
inhibitor
dt
scv
helicas
figur
clear
clone
purifi
e
coli
dnab
helicas
bananin
effect
inhibitor
unstimul
well
character
helicas
polar
atpas
activ
although
slight
inhibit
observ
unwind
puriti
dnab
may
observ
sdspage
figur
found
test
mechan
inhibit
bananin
inhibit
dnab
fretbas
assay
atpas
activ
bananin
check
competit
figur
result
suggest
bananin
respect
atp
figur
respect
dt
figur
figur
act
gener
helicas
inhibitor
potenc
inhibitor
scv
helicas
enzymat
activ
prompt
us
investig
effect
observ
three
day
infect
serial
dilut
therebi
allow
measur
abil
inhibit
scv
replic
cell
cultur
system
chose
test
bananin
viral
titr
studi
drug
ad
either
one
hour
one
hour
infect
repres
class
parent
com
shown
hr
unpublish
data
therefor
read
hr
effect
singl
fect
cpe
cell
appear
inflam
ridg
cell
membran
infect
viru
visual
ingener
seen
data
concentr
bananin
viral
titr
reduc
spection
cell
cultur
infect
scv
presenc
bananin
reveal
cpe
disbi
almost
hr
figur
drug
effect
ad
one
hour
infect
tinctli
reduc
rel
control
infect
result
shown
howev
level
cpe
difficompar
one
hour
drug
ad
remov
addit
viru
cult
quantifi
accur
altern
procedur
pursu
present
rest
experi
hr
differ
addit
drug
afto
quantifi
antivir
activ
bananin
mea
ferenc
scv
sgene
level
control
nonspecif
aggreg
atpas
inhibit
result
consist
helicas
assay
bananin
vanillinbananin
eubananin
iodobananin
best
inhibitor
dnaunwind
ansabanin
adeninobananin
poor
inhibitor
gener
helicas
inhibit
activ
measur
compound
determin
ic
valu
less
correspond
atpas
inhibit
activ
trend
remain
consist
appear
characterist
common
mani
helicas
inhibitor
bananin
act
effect
inhibitor
enzymat
assay
prototyp
member
class
compound
test
first
would
suggest
compound
helicas
sever
structur
unusu
trioxaadainhibit
viral
entri
process
second
suggest
mantan
deriv
trivial
refer
bananin
bananin
may
affect
cellular
pathway
also
show
bananin
exhibit
signific
antiscv
absenc
viral
infect
may
resist
protecact
cell
cultur
inhibit
protiv
effect
drug
scv
helicas
one
poscess
occur
viral
entri
cell
sibl
target
within
cell
although
stage
develop
extrem
conveni
quick
method
exclud
possibl
bananin
may
infor
test
atpas
activ
colorimetr
hibit
via
pathway
helicas
activ
fluorimetr
type
fret
assay
combin
assay
may
adapt
easili
highthroughput
screen
compound
lisignific
brari
ntpase
dnaunwind
enzymat
activ
avoid
use
radioact
p
adamantan
deriv
use
clinic
commonli
use
mani
tradit
helicas
mani
year
antivir
treatment
muscl
reassay
laxant
demonstr
class
atpas
assay
reveal
iodobananin
vanilpyridoxalconjug
trioxaadamantan
banalinbananin
effect
scv
helicas
inhibinin
inhibit
atpas
helicas
activ
tor
atpas
ic
valu
sar
coronaviru
helicas
test
number
respect
bananin
atpas
ic
eubaof
bananin
deriv
shown
imnanin
atpas
ic
also
reason
inhibiport
reduc
steric
hindranc
around
pyritor
ansabananin
adeninobananin
condox
ring
effect
inhibit
scv
helicas
tain
bulki
appendag
pyridox
system
show
furthermor
bananin
shown
effect
littl
inhibit
bananin
act
noncompetiantivir
drug
cell
cultur
viru
mode
tive
inhibitor
respect
atp
nucleic
acid
viral
inhibit
support
hypothesi
suggest
class
inhibitor
bind
site
disscv
helicas
target
compound
given
tinct
atp
nucleic
acid
bind
site
far
pauciti
drug
shown
effect
treat
weaker
inhibit
unstimul
atpas
activ
observ
show
bananin
act
recent
emerg
diseas
bananin
repr
plement
uvvi
spectrophotometri
scv
helicas
domain
access
number
np
synthesi
eugenolbananin
eubananin
eub
origin
denot
clone
purifi
bananin
eugenol
previous
describ
use
protocol
modifi
describ
use
oligodisodium
rel
r
p
r
p
suitabl
helicas
two
oligom
synth
cell
per
well
minimum
essenti
medium
contain
